BSA01 / Biocytogen - LARVOL DELTA

BSA01, a bispecific antibody-drug conjugate targeting EGFR and membrane-bound MUC-1-C, exhibits anti-tumor efficacy in vivo (SITC 2023) - "BSA01 exhibits strong affinity and internalization activity in vitro, while also demonstrating a good safety profile. Moreover, BSA01 shows superior anti-tumor efficacy to benchmarks in certain in vivo PDX models evaluated."

Preclinical • Breast Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Triple Negative Breast Cancer • EGFR • MUC1

Biocytogen Announces 16 Poster Presentations and Booth Exhibition at SITC 2023 (Businesswire) - "Biocytogen Pharmaceuticals (Beijing) Co., Ltd...announced today that the company will be presenting 16 posters and exhibiting at booth 223 at the Society for Immunotherapy of Cancer (SITC) annual conference, taking place from November 1-5, 2023 in San Diego, CA."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer